BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32815829)

  • 1. DDIT3 Immunohistochemistry Is a Useful Tool for the Diagnosis of Myxoid Liposarcoma.
    Scapa JV; Cloutier JM; Raghavan SS; Peters-Schulze G; Varma S; Charville GW
    Am J Surg Pathol; 2021 Feb; 45(2):230-239. PubMed ID: 32815829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear expression of DDIT3 distinguishes high-grade myxoid liposarcoma from other round cell sarcomas.
    Baranov E; Black MA; Fletcher CDM; Charville GW; Hornick JL
    Mod Pathol; 2021 Jul; 34(7):1367-1372. PubMed ID: 33731886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The utility of fluorescence in situ hybridization (FISH) in the diagnosis of myxoid soft tissue neoplasms.
    Downs-Kelly E; Goldblum JR; Patel RM; Weiss SW; Folpe AL; Mertens F; Hartke M; Tubbs RR; Skacel M
    Am J Surg Pathol; 2008 Jan; 32(1):8-13. PubMed ID: 18162764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The utility of fluorescence in situ hybridization (FISH) in determining DNA damage-inducible transcript 3 (DDIT3) amplification in dedifferentiated liposarcomas - an important diagnostic pitfall.
    Kuczkiewicz-Siemion O; Wiśniewski P; Dansonka-Mieszkowska A; Grabowska-Kierył M; Olszewska K; Goryń T; Prochorec-Sobieszek M; Rutkowski P; Szumera-Ciećkiewicz A
    Pathol Res Pract; 2021 Sep; 225():153555. PubMed ID: 34325315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA damage-inducible transcript 3 immunohistochemistry is highly sensitive for the diagnosis of myxoid liposarcoma but care is required in interpreting the significance of focal expression.
    Vargas AC; Chan NL; Wong DD; Zaborowski M; Fuchs TL; Ahadi M; Clarkson A; Sioson L; Sheen A; Maclean F; Bonar F; Cheah A; Jones M; Chou A; Gill AJ
    Histopathology; 2021 Jul; 79(1):106-116. PubMed ID: 33465826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DDIT3 gene break-apart as a molecular marker for diagnosis of myxoid liposarcoma--assay validation and clinical experience.
    Narendra S; Valente A; Tull J; Zhang S
    Diagn Mol Pathol; 2011 Dec; 20(4):218-24. PubMed ID: 22089349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Well-Differentiated Liposarcoma of the Hypopharynx Exhibiting Myxoid Liposarcoma-like Morphology with MDM2 and DDIT3 Co-Amplification.
    Murshed KA; Abo Samra H; Ammar A
    Head Neck Pathol; 2022 Mar; 16(1):288-293. PubMed ID: 34089125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amplification of DNA damage-inducible transcript 3 (DDIT3) is associated with myxoid liposarcoma-like morphology and homologous lipoblastic differentiation in dedifferentiated liposarcoma.
    Mantilla JG; Ricciotti RW; Chen EY; Liu YJ; Hoch BL
    Mod Pathol; 2019 Apr; 32(4):585-592. PubMed ID: 30420727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposarcomas in young patients: a study of 82 cases occurring in patients younger than 22 years of age.
    Alaggio R; Coffin CM; Weiss SW; Bridge JA; Issakov J; Oliveira AM; Folpe AL
    Am J Surg Pathol; 2009 May; 33(5):645-58. PubMed ID: 19194281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NY-ESO-1 is a sensitive and specific immunohistochemical marker for myxoid and round cell liposarcomas among related mesenchymal myxoid neoplasms.
    Hemminger JA; Iwenofu OH
    Mod Pathol; 2013 Sep; 26(9):1204-10. PubMed ID: 23599152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myxoid pleomorphic liposarcoma-a clinicopathologic, immunohistochemical, molecular genetic and epigenetic study of 12 cases, suggesting a possible relationship with conventional pleomorphic liposarcoma.
    Creytens D; Folpe AL; Koelsche C; Mentzel T; Ferdinande L; van Gorp JM; Van der Linden M; Raman L; Menten B; Fritchie K; von Deimling A; Van Dorpe J; Flucke U
    Mod Pathol; 2021 Nov; 34(11):2043-2049. PubMed ID: 34168281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Well-differentiated/dedifferentiated liposarcoma associated with myxoid-like morphology: a clinicopathological and molecular genetic characteristics analysis of 34 cases].
    Xue S; Liu QY; Gou XN; Zhao YW; Cheng Q; Kong LF
    Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):168-173. PubMed ID: 38281785
    [No Abstract]   [Full Text] [Related]  

  • 13. [Pathological significance of NY-ESO-1 expression in the diagnosis of myxoid liposarcoma].
    Hei SM; Wei HJ; Chen H; Wang JG
    Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):225-230. PubMed ID: 30831650
    [No Abstract]   [Full Text] [Related]  

  • 14. The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells.
    Engström K; Willén H; Kåbjörn-Gustafsson C; Andersson C; Olsson M; Göransson M; Järnum S; Olofsson A; Warnhammar E; Aman P
    Am J Pathol; 2006 May; 168(5):1642-53. PubMed ID: 16651630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myxoid liposarcoma with nuclear pleomorphism: a clinicopathological and molecular study.
    Kojima N; Kubo T; Mori T; Satomi K; Matsushita Y; Iwata S; Yatabe Y; Ichimura K; Kawai A; Ichikawa H; Yoshida A
    Virchows Arch; 2024 Jan; 484(1):71-81. PubMed ID: 37704823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary retroperitoneal myxoid/round cell liposarcoma is a nonexisting disease: an immunohistochemical and molecular biological analysis.
    de Vreeze RS; de Jong D; Tielen IH; Ruijter HJ; Nederlof PM; Haas RL; van Coevorden F
    Mod Pathol; 2009 Feb; 22(2):223-31. PubMed ID: 18820664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of TLS/FUS-CHOP fusion transcripts in myxoid and round cell liposarcomas by nested reverse transcription-polymerase chain reaction using archival paraffin-embedded tissues.
    Hisaoka M; Tsuji S; Morimitsu Y; Hashimoto H; Shimajiri S; Komiya S; Ushijima M
    Diagn Mol Pathol; 1998 Apr; 7(2):96-101. PubMed ID: 9785008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myxoid liposarcoma-associated EWSR1-DDIT3 selectively represses osteoblastic and chondrocytic transcription in multipotent mesenchymal cells.
    Suzuki K; Matsui Y; Higashimoto M; Kawaguchi Y; Seki S; Motomura H; Hori T; Yahara Y; Kanamori M; Kimura T
    PLoS One; 2012; 7(5):e36682. PubMed ID: 22570737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric TLS/FUS-CHOP gene expression and the heterogeneity of its junction in human myxoid and round cell liposarcoma.
    Kuroda M; Ishida T; Horiuchi H; Kida N; Uozaki H; Takeuchi H; Tsuji K; Imamura T; Mori S; Machinami R
    Am J Pathol; 1995 Nov; 147(5):1221-7. PubMed ID: 7485386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of CTAG1B clone EPR13780 versus
    Abdelaziz MM; Tayel HY; Abdel-Bary A; Badawy OM
    J Histotechnol; 2022 Jun; 45(2):56-65. PubMed ID: 34845972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.